NCT06589778
A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
StatusUnknown
PhasePhase 1/2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Sep 10, 2024 to Sep 27, 2024
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Determination of Recommended Phase II dose (RP2D)
Timeframe: From first dose of study treatment until the end of Cycle 1(up to 21 days)
Objective Response Rate (ORR)
Timeframe: From time of first dose of SHR-A2102 or Adebrelimab or SHR-8068 until the date of objective disease progression or death (up to 12 months)
Incidence and severity of AEs
Timeframe: The observation period ended at the end of the 21-day period after the first dose of SHR-A2102 or Adebrelimab or SHR-8068 (up to 21 days)
Secondary (4)
Disease Control Rate (DCR)
Duration of Response (DoR)
Progression free Survival (PFS)
Overall Survival (OS)
Arms and interventions
SHR-A2102 in Combination with Adebrelimab and SHR-8068Experimental
Drugs: SHR-A2102, Adebelimab (SHR-1316), SHR-8068
Sites
1 site in 1 country
- Shanghai Chest HospitalShanghai, Shanghai Municipality, China